Heart and Blood Diseases

All Conditions

Neoplasms

Blood and Lymph Conditions

Immune System Diseases

Symptoms and General Pathology

Rare Diseases

Vascular Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Plasmacytoma

Hemostatic Disorders

Blood Coagulation Disorders

Lymphoproliferative Disorders

Paraproteinemias

Neoplasm, Residual

Hematologic Diseases

Hemorrhagic Disorders

Neoplasms by Histologic Type

Blood Protein Disorders

Immunoproliferative Disorders

Lymphatic Diseases

Up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.

CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.

CYNK-001

Adrian Kilcoyne, MD

This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT). The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating Multiple Myeloma.

The study will utilize a 3+3 open label design, and will enroll up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.

Safety Assessment of Dose-Limiting Toxicity (DLT)

Celularity Incorporated

Leukemia

Thrombosis

Hemorrhage

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Lymphoma

Embolism

Embolism and Thrombosis

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Graft Versus Host Disease

Childhood Acute Lymphoblastic Leukemia

Lymphosarcoma

Coagulants

All Drugs and Chemicals

Anticoagulants

Fibrinolytic Agents

Hemostatics

Thrombin

Antithrombins

Antithrombin III

Fibrin fragment D

Thromboplastin

Protein C

Protein S

Standard coagulation tests: APT (Activated Partial Thromboplastin Time), PT/INR (Prothrombin Time Test), Protein-C, Protein-S, Fibrinogen, Antithrombin, D-dimers.

Global haemostasis assays: CAT (Calibrated Automated Thrombogram), OHP (Overall Haemostatic Potential), Fibrin clot turbidity assay, microparticle detection by flow cytometry, scanning electron microscopy.

Protein expression profile (mass spectroscopy)

Ultrasound of catheterised neck veins to detect clots

Coagulopathy parameters

Mats M Heyman, M.D., PhD

Lovisa H Malmqvist, M.D.

The goal of this study is to investigate the hemostatic balance in children with acute lymphoblastic leukaemia (ALL) treated according to the ALLTogether1 protocol with focus on the early treatment period including concomitant use of steroids and asparaginase.

The investigators aim to determine if complement proteins or microparticles can be used as clinically relevant predictive or diagnostic biomarkers for thrombosis and if global hemostatic assays can predict bleeding or thrombosis. Characterization of proteins connected to hemostasis before and during ALL treatment may provide pathophysiological insights regarding ALL- and treatment related coagulopathy. The ultimate goal of the study is to minimize the morbidity and mortality related to thrombosis and bleeding complications in children with ALL.

Several pediatric oncology centers in Sweden will be participating in this study, which will enroll approximately 100 pediatric patients.

Coagulopathy in Childhood Acute Lymphoblastic Leukaemia

Coagulopathy in Childhood Acute Lymphoblastic Leukaemia, Underlying Mechanisms and Ways to Optimise Treatment

When study has been completed and published, IPD may be shared with other researchers on collaborative basis, provided that data protection for study subjects can be ensured and that no violation of data-protection legislation will occur.

Incidence of coagulation events during the induction and consolidation phases (first 106 days of ALL-therapy)

Incidence of laboratory abnormalities during the induction and consolidation phases (first 106 days of ALL-therapy)

Thrombosis detected by ultrasound screening of catheterised neck veins

Karolinska Institutet

Karolinska University Hospital

Associate Professor, Consultant

Thrombocytopenia

Blood Platelet Disorders

Cytopenia

Tranexamic Acid

Antifibrinolytic Agents

Doses will be given intravenous (IV). Doses are administered every 8 hours or three times daily (TID) per the discretion of the treating investigator. TXA dose will be 10mg/kg, diluted in normal saline to a total volume of 15 milliliters (mL).

Doses will be given intravenous (IV). Doses are administered every 8 hours or TID per the discretion of the treating investigator. Normal saline will be administered at a total volume of 15mL.

IV medication administered after patient meets inclusion/exclusion criteria

Normal saline

Meghan McCormick, MD

This study evaluates the use of tranexamic acid (TXA) in addition to standard therapy in children receiving chemotherapy or blood and/or marrow transplantation to decrease the risk of bleeding. Half of participants will receive tranexamic acid and half of participants will receive placebo.

The purpose of this study is to conduct a prospective, randomized, blinded, placebo controlled trial to evaluate the safety and feasibility of the addition of antifibrinolytic therapy with tranexamic acid to the standard care in patients who are thrombocytopenic due to primary bone marrow disorders or chemotherapy, immunotherapy and/or radiation therapy in order to prevent bleeding. The results of this study will change practice by providing evidence as to whether or not TXA is effective and safe treatment when used as an adjunct to platelet transfusion therapy in the thrombocytopenic patient.

This trial is designed as a prospective, randomized, controlled, blinded (patient, caregiver, physician, assessor) trial with two parallel groups and a primary endpoint of feasibility and safety. Randomization will be performed as block randomization with a 1:1 allocation within blocks of size four.

The investigational pharmacy will be notified when patients enroll on trial. When participants meet criteria for randomization, this will be completed by the Investigational Pharmacy. The pharmacy will prepare and distribute to floor nursing staff all doses of tranexamic acid (available in IV form as a colorless liquid) or placebo (as an equal volume of normal saline). Labels will not carry identifiers of which study arm the enrolled patient is on.

A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia

Anonymized public data set will be available after publication of primary results

Adverse Events and Serious Adverse Events (SAE) will be collected on subjects throughout their participation in the study and up to 30 days following discontinuation of the study drug, regardless of attribution. Adverse events and serious adverse events will be tabulated by type and grade according to the NCI CTCAE v 4.03.

The hypothesis is that tranexamic acid can be safely added to standard care regimens in patients with hematologic malignancies or solid tumors during periods of severe thrombocytopenia. Analysis limited to a descriptive assessment of the safety of tranexamic acid in patients with hematologic malignancies or solid tumors by reported adverse events, serious adverse events and death.

Number of participants eligible for study enrollment and recruited.

The hypothesis is that tranexamic acid can be safely added to standard care regimens in patients with hematologic malignancies or solid tumors during periods of severe thrombocytopenia. A descriptive assessment of feasibility of recruitment by monitoring number of patients screened, number of patients eligible for enrollment and rate of recruitment (both start-up and ongoing) during study period to be completed by collecting data on the number of patients screened, the number of patients eligible for study inclusion, the number of eligible patients who consent to study inclusion and the number of consented patients activated to the study drug, organized in visual form by CONSORT diagram.

Proportion of patients with bleeding of WHO grade 2 or above, after activation of study drug. Bleeding graded on a scale ranging from 1 (minor bleeding) through 4 (bleeding that is fatal or life-threatening).

Number of platelet and red blood cell transfusions per patient during the first 30 days post prescription activation of study drug

Number of days alive and without WHO grade 2 bleeding or greater during the first 30 days post activation of study drug. Bleeding graded on a scale ranging from 1 (minor bleeding) through 4 (bleeding that is fatal or life-threatening).

Any venous or arterial thrombosis on standard diagnostic imaging post-randomization

Proportion of patients with bleeding of any grade as assessed by WHO bleeding score, after activation of study drug

Highest grade of bleeding (as measured on WHO bleeding scale) during study period in each enrolled patient. Bleeding graded on a scale ranging from 1 (minor bleeding) through 4 (bleeding that is fatal or life-threatening).

Meghan McCormick

Principal Investigator, Fellow

Doses will be given intravenous (IV). Doses are administered every 8 hours or three times daily (TID) per the discretion of the treating investigator. TXA dose will be 10mg/kg, diluted in normal saline to a total volume of 15 milliliters (mL).

Tranexamic Acid: IV medication administered after patient meets inclusion/exclusion criteria

Doses will be given intravenous (IV). Doses are administered every 8 hours or TID per the discretion of the treating investigator. Normal saline will be administered at a total volume of 15mL.

Normal saline: IV medication administered after patient meets inclusion/exclusion criteria

Placebo

Total

Age, Continuous

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Diagnosis

Type of Therapy

The pre-specified analysis described in the study protocol stated the following: "For secondary endpoints, events of WHO Grade 2 or higher bleeding will be compared through the use of odds ratio or T-test statistic of means. The mean number of platelet transfusions will be analyzed using a T-test statistic of means." This analysis was not completed as it would be scientifically inappropriate due to insufficient enrollment. Instead a descriptive analysis was completed.

Meghan McCormick, MD MS

Grade 3 Adverse Events : Anemia

Grade 3 Adverse Events : Anorexia

Grade 3 Adverse Events : Bone Pain

Grade 3 Adverse Events : Catheter Related Infection

Grade 3 Adverse Events : Vomiting

Grade 3 Adverse Events : Febrile Neutropenia

Grade 3 Adverse Events : Fever

Grade 3 Adverse Events : Hypoalbuminemia

Grade 3 Adverse Events : Hypotension

Grade 3 Adverse Events : Hypoxia

Grade 3 Adverse Events : Hypophosphatemia

Grade 3 Adverse Events : Rash Maculo-Papular

Grade 3 Adverse Events : Nausea

Grade 3 Adverse Events : Mucositis Oral

Grade 3 Adverse Events : Sinusitis

Grade 3 Adverse Events : Skin Infection

Grade 3 Adverse Events : White Blood Cell Decreases

Grade 3 Adverse Events : Platelet Count Decreased

Grade 3 Adverse Events : Blood Bilirubin Increased

Grade 4 Adverse Events : Anemia

Grade 4 Adverse Events : Anorexia

Grade 4 Adverse Events : Bone Pain

Grade 4 Adverse Events : Catheter Related Infection

Grade 4 Adverse Events : Vomiting

Grade 4 Adverse Events : Febrile Neutropenia

Grade 4 Adverse Events : Fever

Grade 4 Adverse Events : Hypoalbuminemia

Grade 4 Adverse Events : Hypotension

Grade 4 Adverse Events : Hypoxia

Grade 4 Adverse Events : Hypophosphatemia

Grade 4 Adverse Events : Rash Maculo-Papular

Grade 4 Adverse Events : Nausea

Grade 4 Adverse Events : Mucositis Oral

Grade 4 Adverse Events : Sinusitis

Grade 4 Adverse Events : Skin Infection

Grade 4 Adverse Events : White Blood Cell Decreases

Grade 4 Adverse Events : Platelet Count Decreased

Grade 4 Adverse Events : Blood Bilirubin Increased

Safety and Tolerability of Tranexamic Acid in Participants as the Number of Patients With Any Adverse Events and Serious Adverse Events (SAE) as Assessed by CTCAE v4.03

Assessed for Eligibility

Screened for Complete Inclusion/Exclusion Criteria

Eligible for Enrollment

Consented to Participate

All patients assessed for eligibility as defined by diagnosis of hematologic or solid tumor malignancy and anticipated platelet counts ≤20,000/uL for ≥5 days

Overall Study

Feasibility of Tranexamic Acid as an Adjunct to Standard Therapy: Number of Participants Eligible and Recruited

World Health Organization (WHO) Bleeding Scale Grade 2 or Higher Bleeding

Number of platelet transfusions per patient

Number of pRBC transfusions per patient

Number of Platelet and Red Blood Cell Transfusions

Number of Days Alive and Without WHO Grade 2 Bleeding or Greater

The Occurrence of Thromboembolic Adverse Events and Serious Adverse Events

Bleeding of Any Grade

Grade 1 Bleeding

Grade 2 Bleeding

Grade 3 Bleeding

Grade 4 Bleeding

Grade 5 Bleeding

Highest Observed Grade of Bleeding (as Measured on WHO Bleeding Scale) During the Study Period

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma	NCT04309084	Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E...	CYNK-001	18 Years - 75 Years	Celularity Incorporated
Coagulopathy in Childhood Acute Lymphoblastic Leukaemia	NCT06242353	Acute Lymphobla... Thrombosis Bleeding Hemostatic Diso...	Coagulopathy pa...	1 Year - 17 Years	Karolinska University Hospital
A Pediatric Trial Using Tranexamic Acid in Thrombocytopenia	NCT03806556	Pediatric Cance... Thrombocytopeni... Hemostatic Diso... Coagulation Def...	Tranexamic Acid Normal saline	2 Years - 21 Years	University of Pittsburgh

Spots Global Cancer Trial Database for hemostatic disorder